Status:
COMPLETED
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Conditions:
Type 2 Diabetes
Type 1 Diabetes
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Diabetes(both types) are recognized by high levels of glucagon in the circulation. Glucagon is known to increase blood glucose, and might therefore contribute to the respective diseases. Under some c...
Eligibility Criteria
Inclusion
- Patients with T2DM
- Above the age of 35 years, treatment with diet or oral anti-diabetic medication. Diagnosed with T2DM in at leat three months in advance(WHO criterion)
- Normal hemoglobin
- Informed content Patients with T1DM
- T1DM (WHO criterion)
- Plasma-C-peptid negative due to arginin-test
- Normal hemoglobin
- age\> 18 years
- Informed content Healthy subjects
- Normal fasting plasma glucose and normal glucose tolerance (WHO criterion)
- Normal hemoglobin
- Age \>18 years
- Informed content
Exclusion
- Patients with T2DM
- Treatment with glitazones and/or gliptins
- Inflammatory bowels disease
- previous bowel resection with or without stomy
- Nephropathy (serum creatinin \>150 µM and/or albuminuria)
- Liver disease (serum alanine-aminotransferase (ALAT) and/or serum aspartate-aminotransferase (ASAT) \>2×normal values)
- Medical treatment impossible to break for 12h.
- Age \>80 years Patients with T1DM
- Overweight (BMI \>30 kg/m2)
- Inflammatory bowels disease
- previous bowel resection with or without stomy
- Nephropathy (serum creatinin \>150 µM and/or albuminuria)
- Liver disease (serum alanine-aminotransferase (ALAT) and/or serum aspartate-aminotransferase (ASAT) \>2×normal values)
- Medical treatment impossible to break for 12h (except treatment with insulin).
- Age \>80 years
- Healthy subjects
- Diabetes
- Prediabetes (impaired glucose tolerance and/or impaired fasting plasma glucose)
- First order relatives with diabetes
- Overweight (BMI \>30 kg/m2)
- Inflammatory bowels disease
- previous bowel resection with or without stomy
- Nephropathy (serum creatinin \>150 µM and/or albuminuria)
- Liver disease (serum alanine-aminotransferase (ALAT) and/or serum aspartate-aminotransferase (ASAT) \>2×normal values)
- Medical treatment impossible to break for 12h.
- Age \>80 years
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01507597
Start Date
December 1 2011
End Date
August 1 2013
Last Update
December 10 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gentofte University Hospital
Hellerup, Denmark, DK-2900